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Purpose: To identify the underlying genetic cause in a two generation German family diagnosed with isolated aniridia.
Methods: All patients underwent full ophthalmic examination. Mutation screening of the paired box gene 6 (PAX6) was
performed by bidirectional Sanger sequencing. A minigene assay was applied to analyze transcript processing of mutant
and wildtype PAX6 variants in HEK293 cells.
Results: We identified a PAX6 sequence variant at the splice donor site (+5) of intron 12. This variant has been described
before in another family with aniridia but has not been characterized at the transcript level. We could demonstrate that
the mutant allele causes the skipping of exon 12 during transcript processing. The mutation is predicted to result in a ‘run
on’ translation past the normal translational stop codon.
Conclusions: A splice site mutation resulting in exon skipping was found in a family with autosomal dominant aniridia.
The mutation is predicted to result in an enlarged protein with an extra COOH-terminal domain. This very likely affects
the transactivation properties of the PAX6 protein.
Aniridia is a rare, bilateral, congenital ocular disorder
causing incomplete formation of the iris. The degree of iris
hypoplasia is variable, ranging from minimal loss of iris tissue
to nearly complete absence. The visual impairment caused by
iris  hypoplasia  might  be  enhanced  by  several  ocular
complications,  including  cataract,  glaucoma  and  corneal
clouding.  Aniridia  can  be  associated  with  extra-ocular
anomalies, including Wilms tumor, genitourinary anomalies
and  mental  retardation  (OMIM  194072);  absent  patella
(OMIM 106220); and cerebellar ataxia and mental retardation
(OMIM  206700).  In  isolated  aniridia  (OMIM  106210),
familial cases are relatively frequent and characterized by an
autosomal dominant mode of inheritance [1]. Most, if not all
cases with isolated aniridia, can be attributed to mutations in
the paired box gene 6 (PAX6) [2]. PAX6 is a member of the
PAX  multigene  family  of  transcription  factors  that  are
involved in embryonic differentiation [3,4].
Numerous PAX6 mutations have been detected in patients
with aniridia. A compilation of these mutations can be found
in  the  Human  PAX6  Mutation  Database  [5].  Most  of
mutations are nonsense mutations, splice site mutations or
insertion/deletions which are predicted to result in premature
termination codons. The remaining mutations are missense or
run-on mutations [6].
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The  aim  of  the  present  study  was  to  identify  the
underlying genetic cause in a Germany family with autosomal
dominant aniridia.
METHODS
Patients: Four family members in two successive generations
were  diagnosed  with  apparently  isolated  aniridia  at  the
University Eye Hospital in Wuerzburg, Germany. Ophthalmic
examination  included  best  corrected  visual  acuity,
measurement of intraocular pressure, slit lamp examination,
and funduscopy.
Informed consent, conform to the Institutional Review
Board requirements, were obtained from two individuals to
participate in the molecular genetic study. Genomic DNA was
extracted from peripheral blood leukocytes using standard
protocols.
Mutation screening: Mutation screening of the PAX6 gene
(RefSeq:  NM_000280.3)  was  performed  by  bidirectional
Sanger sequencing. Gene specific PCR primers were designed
and used to amplify individual exons and flanking intron
sequences applying standard PCR amplification protocols.
Primer sequences are given in Table 1. PCR fragments were
purified  by  ExoSAP-IT  treatment  (USB,  Cleveland,  OH),
sequenced using Big Dye Termination chemistry (Applied
Biosystems  [ABI],  Weiterstadt,  Germany)  and  products
separated on a DNA capillary sequencer (ABI 3100 genetic
analyzer; ABI, Weiterstadt, Germany).
Heterologous splicing assay: A 662-bp genomic segment of
PAX6 covering exon 12 with adjacent intronic sequences was
amplified from patient genomic DNA using specific primers
carrying 5′tails with NotI and BamHI recognition sequences.
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751Since the variant c.1183+5G>A was present in heterozygous
state in our patients, both the normal and the variant allele
could be co-amplified. The PCR fragment was then cloned
into  the  pCR2.1  plasmid  (Invitrogen-Life  Technologies,
Karlsruhe,  Germany).  Cloned  inserts  were  sequenced  to
identify clones carrying the normal c.1183+5 G-allele or the
Figure  1.  Pedigree  of  family.  The  family  history  revealed  four
affected members in two generations. Squares and circles symbolize
males  and  females,  respectively.  Clear  and  blackened  symbols
denote unaffected and affected individuals. Patients I:1, I:2, I:3, and
II:1 were clinically analyzed; blood samples for genetic analysis
were available for patients I:1 and II:1.
mutant c.1183+5 A-allele. Wildtype and mutant inserts were
excised by digestion with BamHI and NotI and cloned into
BamHI/NotI– digested pSPL3_2096 (a derivative of the exon-
trapping vector pSPL3 [Invitrogen-Life Technologies], with
a stuffer fragment cloned into the original NotI site).
HEK  293  cells  were  cultured  in  DMEM  medium
supplemented with 10% FBS at 37 °C, in 5% CO2. Six-well
plates were used and the cells were cultured up to 75% of
confluence.  Cells  were  transfected  with  pSPL3-PAX6
constructs  with  transfection  reagent  (Lipofectamine;
Invitrogen-Life  Technologies)  according  to  the
manufacturer's  instructions.  As  a  control,  cells  were
transfected with pSPL3 lacking the PAX6 insert. Total RNA
was extracted 24 h after transfection with the RNAEasy Mini
Kit (Qiagen, Hilden, Germany). Reverse transcription was
performed applying the SA2 primer (a reverse primer located
on the 3′tat exon of the pSPL3 vector) and the Transcriptor
High Fidelity cDNA Synthesis Kit (Roche Applied Science,
Mannheim, Germany). The cDNA was PCR amplified with
pSPL3 exon primers and sequenced as described above.
RESULTS
Four family members from two successive generations of a
German family underwent repeated ophthalmic examination.
A diagnosis of isolated aniridia was made according to the fact
that  Wilm’s  tumor  and  urogenital  anomalies  could  be
excluded in the patients and neurodevelopmental delay was
not evident. However, a syndromic form of aniridia associated
TABLE 1. PRIMER SEQUENCES FOR PCR AMPLIFICATION OF PAX6.
Primer name Primer sequence Annealing temperature
(°C)
Amplicon size
(bp)
PAX6-Exon4-f tgtaggggaaacaga 55 491
PAX6-Exon4-r atcgagaagagccaagcaaa    
PAX6-Exon5-f ctggtggtcctgttgtcctt 55 446
PAX6-Exon5-r atgaagagagggcgttgaga    
PAX6-Exon6-f gggctacaaatgtaattttaagaa 55 509
PAX6-Exon6-r agagagggtgggaggaggta    
PAX6-Exon7-f gagctgagatgggtgactg 55 300
PAX6-Exon7-r gagagtaggggacaggcaaa    
PAX6-Exon8-f tcaggtaactaacatcgca 55 719
PAX6-Exon8-r gttgactgtacttggaagaa    
PAX6-Exon9-f aggtgggaaccagtttgatg 55 311
PAX6-Exon9-r catggcagcagagcatttag    
PAX6-Exon10-f gctaaatgctctgctgccat 55 329
PAX6-Exon10-r agagtgagagtcagagcccg    
PAX6-Exon11-f ccgggctctgactctcact 55 221
PAX6-Exon11-r gccactcctcacttctctgg    
PAX6-Exon12-f gaggcttgatacataggc 55 452
PAX6-Exon12-r ccataagaccaggagatt    
PAX6-Exon13-f tccatgtctgtttctcaaagg 55 220
PAX6-Exon13-r tcaactgttgtgtccccatag    
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752with brain abnormalities could not be excluded since magnetic
resonance  imaging  was  not  performed.  Follow-up  ranged
from four years (patient II:1) to 40 years (patient I:1). The
pedigree of the family is given in Figure 1. Absent or nearly
absent  irides  as  well  as  upward  lens  dislocation  were
diagnosed  in  all  four  patients.  Patients  I:2  and  I:3  also
presented with congenital cataract. Ophthalmic findings are
compared and summarized in Table 2 and selected clinical
features of two probands are shown in Figure 2.
Bidirectional sequencing of PAX6 exons did not reveal
any  causative  alteration  but  the  analysis  of  exon/intron
boundaries  resulted  in  the  identification  of  a  nucleotide
substitution at the splice donor sequence of intron 12 (Figure
3). Using online resources, we evaluated the presumptive
effect of this variant on the splice donor site. The wild-type
and mutant sequences (exon 12 plus approximately 250 bp of
each of the adjacent introns) were submitted to three different
splicing prediction tools: NNSPLICE [7], Geneid [8], and
HSF [9]. As predicted by all three tools, the variant sequence
substantially decreased the recognition of the intron 12 donor
site (Table 3). We therefore reasoned that the c.1183+5G>A
substitution  affects  splicing  of  PAX6  and  tested  this
substitution  in  a  heterologous  splicing  assay.  A  genomic
segment  that  included  the  complete  exon  12  plus
approximately 250 bp of each of the adjacent introns was
amplified from patient II:1 and cloned into the exon trapping
vector pSPL3. HEK 293 cells were transfected with plasmids
carrying either the normal c.1183+5 G-allele or the mutant c.
1183+5 A-allele, and RT–PCR products were amplified from
RNA of transfected cell cultures with vector-specific primers.
Cultures transfected with plasmid constructs with the mutant
c.1183+5 A-allele yielded RT–PCR products that were clearly
smaller  than  products  from  cultures  transfected  with  the
normal c.1183+5 G-allele (Figure 4), indicating abnormal
splicing  of  the  mutant  minigene  construct.  Subsequent
sequencing of the RT–PCR products showed that RT–PCR
products derived from the transfection with the mutant c.
1183+5 A-allele lacked exon 12 of the PAX6 gene (Figure 5).
As a result of this skipping of exon 12 which comprises 151
bp,  the  c.1183+5G>A  variant  is  predicted  to  change  the
reading  frame.  Due  to  the  lack  of  premature  termination
codons of this alternative reading frame, the deduced mutant
polypeptide is larger than the wildtype PAX6 containing an
extended COOH-terminal sequence (Figure 6).
DISCUSSION
Upon bidirectional Sanger sequencing of all coding exons and
exon-intron boundaries of PAX6, we identified a sequence
TABLE 2. CLINICAL FEATURES OF PROBANDS.
Patient Aniridia Lens subluxation Congenital cataract Congenital
nystagmus
Secondary
glaucoma
I:1 + + - - +
I:2 + + + + +
I:3 + + + - +
II:1 + + - - -
Figure 2. Retroillumination anterior segment photographs of affected family members. Proband II:1 shows total aniridia (A); proband I:2
shows subluxated cataractous lens (B).
Molecular Vision 2012; 18:751-757 <http://www.molvis.org/molvis/v18/a80> © 2012 Molecular Vision
753variant in the splice donor site of intron 12 (c.1183+5G>A).
Although this variant has been described before in a small
Swiss family (affected mother and son) with isolated aniridia
[10], the pathogenic nature of the mutation has never been
confirmed. Unlike the first and second positions of the splice
donor sequence, the fifth is not invariant and the consequence
of  this  change  can  only  be  tested  by  RNA  analysis.  To
circumvent the lack of PAX6 expression in accessible tissues,
we made use of a heterologous splicing assay to test in direct
comparison mutant and wildtype PAX6 minigene constructs.
Human PAX6 encodes a 422 amino acid transcription factor
with  two  DNA-binding  domains:  a  paired  domain  at  the
NH2-terminus and a homeodomain in the center of the protein.
The COOH-terminal segment is rich in proline, serine, and
threonine  residues  (PST  domain)  and  constitutes  the
transactivating domain of the protein [11]. The PST domain
is encoded by exons 10, 11, 12, and 13. The skipping of exon
12 as demonstrated in our family is predicted to result in a
Figure 3. Forward sequence analysis of
exon  12  (highlighted  in  blue)  and
adjacent intronic sequence of the PAX6
gene in patient II:1 (upper panel) and a
healthy  control  person  (lower  panel).
The  arrow  indicates  the  heterozygous
G>A transition in intron 12 at position
+5.
TABLE 3. IN SILICO PREDICTION SCORE VALUES FOR THE INTRON 12 DONOR SPLICE SITE OF THE PAX6 WILDTYPE AND MUTANT ALLELES.
Splicing prediction tool Wildtype* Mutant
NNSplice 1.00 0.74
Geneid 4.49 2.01
HSF 0.97 0.85
          *The higher the value, the higher the probability of being a splice site in vivo.
Figure 4. Agarose gel electrophoresis of
RT–PCR products. RNA was derived
from HEK293 cells transfected with the
wildtype  c.1183+5  G-allele  plasmid
construct (lane 1), the mutant c.1183+5
A-allele plasmid construct (lane 2) and
the empty pSPL3 vector (lane 3). M, size
ladder (100 bp ladder, Fermentas, St.
Leon-Rot, Germany). The RT–PCR for
the empty pSPL3 vector gives rise to a
PCR product of 263 bp. Exon 12 of the
PAX6 gene comprises 151 nucleotides.
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754frameshift  and  ‘run  on’  translation  past  the  normal
translational stop codon, thus generating an enlarged protein
with an extra COOH-terminal domain. This very likely affects
the transactivating domain of the protein. Skipping of exon 12
has also been demonstrated by Hanson and coworkers [12,
13] in two aniridia families that had a deletion of the first 3 bp
of intron 12 and a substitution of the last base of exon 12,
respectively. Two other mutations in the splice donor site of
intron 12 have been identified which probably also result in
the out-of-frame skipping of exon 12 and a ´run on´ transcript,
however, these have not been characterized on the RNA level
[14,15]. These findings substantiate our hypothesis that the
p.P345DfsX130  mutation  is  the  underlying  cause  for  the
aniridia phenotype in our family. However, the functional
significance of this mutation can only be assessed by in vivo
transcriptional activation assays.
We observed a considerable phenotypic variability in our
family (Table 1). Some features as upward lens dislocation
could be seen in all members. The degree of iris hypoplasia
was  also  strikingly  similar.  On  the  other  hand,  only  two
patients had congenital cataract and only one had nystagmus.
PAX6  exerts  its  function  through  a  complex  pathway.
Therefore it is not surprising that the phenotypic outcome of
any  particular  mutation  is  dependent  on  an  individual’s
genetic  background.  In  fact,  phenotypic  variability,  either
intra- or interfamilial, is often observed in aniridia [16-18].
Given  that  aniridia  is  a  rare  disease,  genotype-phenotype
correlations are difficult to assess. The most comprehensive
analysis has been performed by Hingorani and colleagues
[19]. The authors analyzed phenotypic data of 43 individuals
diagnosed  with  aniridia  or  aniridia-like  phenotypes  and
grouped them according to the type of mutation found in the
PAX6 gene (loss-of-function mutations, missense mutations,
and  COOH-terminal  extension  (CTE)  mutations).  They
observed  considerable  phenotypic  variability  within  each
group  but  also  noticed  that  individuals  with  missense
mutations had the mildest phenotypes with better preserved
iris structures. In their cohort of ten individuals with CTE-
Figure 5. Sequence analysis of RT–PCR
products.  RNA  was  derived  from
HEK293  cells  transfected  with  the
wildtype  c.1183+5  G-allele  plasmid
construct (A) and the mutant c.1183+5
A-allele plasmid construct (B). A: Red
letters indicate the tat exon 1 sequence
and black letters indicate sequence of
PAX6 exon 12. B: Red letters indicate
the tat exon 1 sequence and green letters
indicate the tat exon 2 sequence.
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755mutations, two were diagnosed with exudative retinopathy.
More  recently,  Aggarwal  and  colleagues  [15]  reported  a
family with a mutation in the splice donor site of PAX6 intron
12. Although not demonstrated experimentally, the mutation
is  predicted  to  result  in  CTE.  The  authors  state  that  the
presence of chorioretinal degeneration in one of the affected
individual  raises  the  possibility  that  CTE-mutations  are
associated  with  chorioretinal  involvement  in  aniridia.  We
cannot  substantiate  this  hypothesis.  Chorioretinal
involvement was excluded in our patients, except for patient
I:2 in whom fundoscopy was compromised by nystagmus.
Whether  CTE  alleles  of  PAX6  in  fact  provoke  a  distinct
phenotypic outcome remains to be established and requires
the analysis of further patients.
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